FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216014740> ?p ?o ?g. }

• W3216014740 abstract "Data on the use of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation are limited. The current study aimed to assess the efficacy of ICIs in EGFR-mutant advanced NSCLC and explore the relevant influential factors.Relevant clinical data of EGFR-mutant NSCLC patients who had received ICIs were collected from multiple hospitals. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), and relevant influential factors.A total of 122 advanced EGFR-mutant NSCLC patients were included in the final analysis. The total cohort had an objective response rate (ORR) of 32.0%, a median progression-free survival (mPFS) of 5.0 months, and a median overall survival (mOS) of 14.4 months. Among 96 patients with common EGFR mutations (19Del, 52 patients; L858R, 44 patients), those who were administered front-line ICI exhibited better survival benefits than those who received later-line ICI after disease progression on tyrosine kinase inhibitors (TKIs) treatment (mPFS: 7.2 months vs. 3.4 months, respectively, P < 0.0001; mOS: 15.1 months vs. 8.4 months, respectively, P <0.0001). Moreover, the efficacy of ICI-based combination therapy was better than that of ICI monotherapy (mPFS: 5.0 months vs. 2.2 months, respectively, P = 0.002; mOS: 14.4 months vs. 7.0 months, respectively, P = 0.001). Multivariate analysis showed that ICI-based combination therapy and front-line ICI administration after progression on EGFR-TKI were associated with significant improvements in both PFS and OS (P < 0.05). A high PD-L1 expression (tumor proportion score, TPS≥50%) and the EGFR L858R mutation were only significantly associated with a better PFS (P <0.05). A better Eastern Cooperative Oncology Group (ECOG) status was independently associated with a favorable OS (P <0.05).Taken together, combination immunotherapy in front-line was associated with improvement of survival in EGFR-mutant NSCLC patients post-TKI resistance. Further prospective studies with large sample sizes are required to identify the optimal combinatorial treatment strategy." @default.
• W3216014740 created "2021-12-06" @default.
• W3216014740 creator A5023750583 @default.
• W3216014740 creator A5038043249 @default.
• W3216014740 creator A5053307667 @default.
• W3216014740 creator A5053384731 @default.
• W3216014740 creator A5059912107 @default.
• W3216014740 creator A5061645783 @default.
• W3216014740 creator A5063627915 @default.
• W3216014740 creator A5064100733 @default.
• W3216014740 creator A5067166395 @default.
• W3216014740 creator A5076344513 @default.
• W3216014740 creator A5078143614 @default.
• W3216014740 creator A5081704912 @default.
• W3216014740 creator A5086334551 @default.
• W3216014740 date "2021-11-23" @default.
• W3216014740 modified "2023-10-18" @default.
• W3216014740 title "Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation" @default.
• W3216014740 cites W1911271782 @default.
• W3216014740 cites W1982488143 @default.
• W3216014740 cites W2003984225 @default.
• W3216014740 cites W2071480068 @default.
• W3216014740 cites W2081801534 @default.
• W3216014740 cites W2123918574 @default.
• W3216014740 cites W2152481222 @default.
• W3216014740 cites W2160982674 @default.
• W3216014740 cites W2560367415 @default.
• W3216014740 cites W2560717039 @default.
• W3216014740 cites W2567564314 @default.
• W3216014740 cites W2572174216 @default.
• W3216014740 cites W2611484367 @default.
• W3216014740 cites W2627045858 @default.
• W3216014740 cites W2765696340 @default.
• W3216014740 cites W2765962239 @default.
• W3216014740 cites W2777461561 @default.
• W3216014740 cites W2791328450 @default.
• W3216014740 cites W2797645911 @default.
• W3216014740 cites W2853824599 @default.
• W3216014740 cites W2889653218 @default.
• W3216014740 cites W2894023816 @default.
• W3216014740 cites W2903663678 @default.
• W3216014740 cites W2913134141 @default.
• W3216014740 cites W2916877067 @default.
• W3216014740 cites W2919091706 @default.
• W3216014740 cites W2924289105 @default.
• W3216014740 cites W2944860885 @default.
• W3216014740 cites W2946166987 @default.
• W3216014740 cites W2972582992 @default.
• W3216014740 cites W2990409488 @default.
• W3216014740 cites W3000415041 @default.
• W3216014740 cites W3011940221 @default.
• W3216014740 cites W3017038549 @default.
• W3216014740 cites W3039432873 @default.
• W3216014740 cites W3041955255 @default.
• W3216014740 cites W3044933172 @default.
• W3216014740 cites W3098529833 @default.
• W3216014740 cites W3135862196 @default.
• W3216014740 cites W3136831243 @default.
• W3216014740 cites W3154805493 @default.
• W3216014740 cites W3157623590 @default.
• W3216014740 cites W3159640891 @default.
• W3216014740 cites W3170503974 @default.
• W3216014740 cites W3186228900 @default.
• W3216014740 cites W3200117455 @default.
• W3216014740 cites W3205552647 @default.
• W3216014740 doi "https://doi.org/10.3389/fonc.2021.739090" @default.
• W3216014740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34888234" @default.
• W3216014740 hasPublicationYear "2021" @default.
• W3216014740 type Work @default.
• W3216014740 sameAs 3216014740 @default.
• W3216014740 citedByCount "16" @default.
• W3216014740 countsByYear W32160147402022 @default.
• W3216014740 countsByYear W32160147402023 @default.
• W3216014740 crossrefType "journal-article" @default.
• W3216014740 hasAuthorship W3216014740A5023750583 @default.
• W3216014740 hasAuthorship W3216014740A5038043249 @default.
• W3216014740 hasAuthorship W3216014740A5053307667 @default.
• W3216014740 hasAuthorship W3216014740A5053384731 @default.
• W3216014740 hasAuthorship W3216014740A5059912107 @default.
• W3216014740 hasAuthorship W3216014740A5061645783 @default.
• W3216014740 hasAuthorship W3216014740A5063627915 @default.
• W3216014740 hasAuthorship W3216014740A5064100733 @default.
• W3216014740 hasAuthorship W3216014740A5067166395 @default.
• W3216014740 hasAuthorship W3216014740A5076344513 @default.
• W3216014740 hasAuthorship W3216014740A5078143614 @default.
• W3216014740 hasAuthorship W3216014740A5081704912 @default.
• W3216014740 hasAuthorship W3216014740A5086334551 @default.
• W3216014740 hasBestOaLocation W32160147401 @default.
• W3216014740 hasConcept C121608353 @default.
• W3216014740 hasConcept C126322002 @default.
• W3216014740 hasConcept C143998085 @default.
• W3216014740 hasConcept C203092338 @default.
• W3216014740 hasConcept C2776256026 @default.
• W3216014740 hasConcept C2776999253 @default.
• W3216014740 hasConcept C2779438470 @default.
• W3216014740 hasConcept C2780580887 @default.
• W3216014740 hasConcept C2780739268 @default.
• W3216014740 hasConcept C3019894029 @default.
• W3216014740 hasConcept C535046627 @default.
• W3216014740 hasConcept C71924100 @default.

• next